Working… Menu
Trial record 91 of 178 for:    LENALIDOMIDE AND Leukemia

Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (LENAMAINT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00720850
Recruitment Status : Terminated (Low recruitment, scientific rationale not applicable anymore to all patients and possible induction of GvHD by the study drug)
First Posted : July 23, 2008
Last Update Posted : September 27, 2013
Celgene Corporation
Information provided by (Responsible Party):
Technische Universität Dresden

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : January 2011
Actual Study Completion Date : January 2011